Edgewise Therapeutics Reports Two-Year Topline Results From ARCH Open Label Trial Of Sevasemten In Adults With Becker Muscular Dystrophy; Sevasemten Was Well-Tolerated
Author: Benzinga Newsdesk | April 15, 2024 04:08pm
"We are pleased by the promising and consistent functional results observed over two years of treatment with sevasemten, together with the favorable safety and tolerability profile," said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Edgewise. "We thank the Becker community for engaging with us on this promising therapy."
Posted In: EWTX